Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 136

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Mechanisms of statin-associated skeletal muscle-associated symptoms

Bouitbir, Jamal, Sanvee, Gerda M., Panajatovic, Miljenko V., Singh, François, Krähenbühl, Stephan·2020·Pharmacological Research
DOI 10.1016/j.phrs.2019.03.010
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.phrs.2019.03.010

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Research works printed but not linked: 104

  1. Tobert, 2003, Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors, Nat. Rev. Drug Discov., 2, 517, 10.1038/nrd1112 · DOI · Paper page
  2. Mabuchi, 1983, Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine, N. Engl. J. Med., 308, 609, 10.1056/NEJM198303173081101 · DOI
  3. Alberts, 1980, Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent, Proc. Natl. Acad. Sci. U. S. A., 77, 3957, 10.1073/pnas.77.7.3957 · DOI · Paper page
  4. Goldstein, 2006, Protein sensors for membrane sterols, Cell, 124, 35, 10.1016/j.cell.2005.12.022 · DOI · Paper page
  5. Walley, 2004, Variations and increase in use of statins across Europe: data from administrative databases, BMJ, 328, 385, 10.1136/bmj.328.7436.385 · DOI
  6. Stroes, 2015, Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management, Eur. Heart J., 36, 1012, 10.1093/eurheartj/ehv043 · DOI · Paper page
  7. Gu, 2014, Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012, NCHS Data Brief, 177, 1
  8. Wallach-Kildemoes, 2016, Statin prescribing according to gender, age and indication: what about the benefit-risk balance?, J. Eval. Clin. Pract., 22, 235, 10.1111/jep.12462 · DOI
  9. Farrer, 2018, Beyond statins: emerging evidence for HDL-Increasing therapies and diet in treating cardiovascular disease, Adv. Prev. Med., 2018, 10.1155/2018/6024747 · DOI
  10. Eriksson, 2011, Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial, Adv. Ther., 28, 811, 10.1007/s12325-011-0056-7 · DOI
  11. Kikutani, 2016, Involvement of monocarboxylate transporter 4 expression in statin-induced cytotoxicity, J. Pharm. Sci., 105, 1544, 10.1016/j.xphs.2016.01.014 · DOI
  12. Ratz Bravo, 2005, Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy, Drug Saf., 28, 263, 10.2165/00002018-200528030-00007 · DOI
  13. Roten, 2004, Rhabdomyolysis in association with simvastatin and amiodarone, Ann. Pharmacother., 38, 978, 10.1345/aph.1D498 · DOI
  14. McKenney, 2003, Pharmacologic characteristics of statins, Clin. Cardiol., 26
  15. Profumo, 2014, Pleiotropic effects of statins in atherosclerotic disease: focus on the antioxidant activity of atorvastatin, Curr. Top. Med. Chem., 14, 2542, 10.2174/1568026614666141203130324 · DOI
  16. Antoniades, 2014, Statins: pleiotropic regulators of cardiovascular redox state, Antioxid. Redox Signal., 20, 1195, 10.1089/ars.2014.5836 · DOI
  17. Thompson, 2016, Statin-associated side effects, J. Am. Coll. Cardiol., 67, 2395, 10.1016/j.jacc.2016.02.071 · DOI · Paper page
  18. Maghsoodi, 2016, Statin myopathy: over-rated and under-treated?, Curr. Opin. Cardiol., 31, 417, 10.1097/HCO.0000000000000282 · DOI
  19. Group, 2002, Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up, Lancet, 359, 1379, 10.1016/S0140-6736(02)08351-4 · DOI · Paper page
  20. Sever, 2003, Lancet, 361, 1149, 10.1016/S0140-6736(03)12948-0 · DOI · Paper page
  21. Tomlinson, 2005, Potential adverse effects of statins on muscle, Phys. Ther., 85, 459, 10.1093/ptj/85.5.459 · DOI
  22. Meador, 2010, Statin-associated myopathy and its exacerbation with exercise, Muscle Nerve, 42, 469, 10.1002/mus.21817 · DOI
  23. Sinzinger, 2004, Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems, Br. J. Clin. Pharmacol., 57, 525, 10.1111/j.1365-2125.2003.02044.x · DOI
  24. Mancini, 2011, Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference, Can. J. Cardiol., 27, 635
  25. Kipfer, 2015, Immune-mediated necrotising myopathy linked to statin use, Lancet, 386, 10.1016/S0140-6736(15)60068-X · DOI
  26. Kobayashi, 2008, Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins, Life Sci., 82, 969, 10.1016/j.lfs.2008.02.019 · DOI
  27. Mullen, 2010, Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy, Biochem. Pharmacol., 79, 1200, 10.1016/j.bcp.2009.12.007 · DOI
  28. Morita, 1997, Enhancement of membrane fluidity in cholesterol-poor endothelial cells pre-treated with simvastatin, Endothelium, 5, 107, 10.3109/10623329709079868 · DOI
  29. Nakahara, 1994, Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors, Biochem. Biophys. Res. Commun., 202, 1579, 10.1006/bbrc.1994.2112 · DOI
  30. Sun, 2018, Atorvastatin impaired glucose metabolism in C2C12 cells partly via inhibiting cholesterol-dependent glucose transporter 4 translocation, Biochem. Pharmacol., 150, 108, 10.1016/j.bcp.2018.01.021 · DOI
  31. Epstein, 1991, Quantitation of prenylcysteines by a selective cleavage reaction, Proc. Natl. Acad. Sci. U. S. A., 88, 9668, 10.1073/pnas.88.21.9668 · DOI
  32. Wang, 2016, Protein prenylation: unique fats make their mark on biology, Nat. Rev. Mol. Cell Biol., 17, 110, 10.1038/nrm.2015.11 · DOI · Paper page
  33. Kato, 1992, Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity, Proc. Natl. Acad. Sci. U. S. A., 89, 6403, 10.1073/pnas.89.14.6403 · DOI · Paper page
  34. Yang, 2012, Cooperative activation of PI3K by Ras and Rho family small GTPases, Mol. Cell, 47, 281, 10.1016/j.molcel.2012.05.007 · DOI
  35. Sebti, 2005, Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy, Cancer Cell, 7, 297, 10.1016/j.ccr.2005.04.005 · DOI
  36. du Souich, 2017, Myotoxicity of statins: mechanism of action, Pharmacol. Ther., 175, 1, 10.1016/j.pharmthera.2017.02.029 · DOI
  37. Flint, 1997, HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture, Toxicol. Appl. Pharmacol., 145, 99, 10.1006/taap.1997.8174 · DOI
  38. Shah, 2018, Ras and Rap1: a tale of two GTPases, Semin. Cancer Biol.
  39. Jaskiewicz, 2018, Geranylgeraniol prevents statin-dependent myotoxicity in C2C12 muscle cells through RAP1 GTPase prenylation and cytoprotective autophagy, Oxid. Med. Cell. Longev., 2018, 10.1155/2018/6463807 · DOI
  40. Johnson, 2004, Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone, Toxicol. Appl. Pharmacol., 200, 237, 10.1016/j.taap.2004.04.010 · DOI
  41. Gee, 2015, Inhibition of prenyltransferase activity by statins in both liver and muscle cell lines is not causative of cytotoxicity, Toxicology, 329, 40, 10.1016/j.tox.2015.01.005 · DOI
  42. JeBailey, 2007, Ceramide- and oxidant-induced insulin resistance involve loss of insulin-dependent Rac-activation and actin remodeling in muscle cells, Diabetes, 56, 394, 10.2337/db06-0823 · DOI
  43. Kanzaki, 2006, Insulin receptor signals regulating GLUT4 translocation and actin dynamics, Endocr. J., 53, 267, 10.1507/endocrj.KR-65 · DOI
  44. Sylow, 2014, Akt and Rac1 signaling are jointly required for insulin-stimulated glucose uptake in skeletal muscle and downregulated in insulin resistance, Cell. Signal., 26, 323, 10.1016/j.cellsig.2013.11.007 · DOI
  45. Sylow, 2013, Rac1 is a novel regulator of contraction-stimulated glucose uptake in skeletal muscle, Diabetes, 62, 1139, 10.2337/db12-0491 · DOI
  46. Chiu, 2011, Rac1 signalling towards GLUT4/glucose uptake in skeletal muscle, Cell. Signal., 23, 1546, 10.1016/j.cellsig.2011.05.022 · DOI
  47. Sylow, 2013, Rac1 signaling is required for insulin-stimulated glucose uptake and is dysregulated in insulin-resistant murine and human skeletal muscle, Diabetes, 62, 1865, 10.2337/db12-1148 · DOI
  48. Li, 2016, Simvastatin inhibits glucose uptake activity and GLUT4 translocation through suppression of the IR/IRS-1/Akt signaling in C2C12 myotubes, Biomed. Pharmacother., 83, 194, 10.1016/j.biopha.2016.06.029 · DOI
  49. Baker, 2005, Molecular clues into the pathogenesis of statin-mediated muscle toxicity, Muscle Nerve, 31, 572, 10.1002/mus.20291 · DOI
  50. Sanvee, 2019, Mechanisms of insulin resistance by simvastatin in C2C12 myotubes and in mouse skeletal muscle, Biochem. Pharmacol., 10.1016/j.bcp.2019.02.025 · DOI
  51. Nunnari, 2012, Mitochondria: in sickness and in health, Cell, 148, 1145, 10.1016/j.cell.2012.02.035 · DOI · Paper page
  52. Sirvent, 2008, New insights into mechanisms of statin-associated myotoxicity, Curr. Opin. Pharmacol., 8, 333, 10.1016/j.coph.2007.12.010 · DOI
  53. Bouitbir, 2016, Statins trigger mitochondrial reactive oxygen species-induced apoptosis in glycolytic skeletal muscle, Antioxid. Redox Signal., 24, 84, 10.1089/ars.2014.6190 · DOI
  54. Kaufmann, 2006, Toxicity of statins on rat skeletal muscle mitochondria, Cell. Mol. Life Sci., 63, 2415, 10.1007/s00018-006-6235-z · DOI · Paper page
  55. Mullen, 2011, Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt, Biochim. Biophys. Acta, 1813, 2079, 10.1016/j.bbamcr.2011.07.019 · DOI
  56. Singh, 2018, PGC-1beta modulates statin-associated myotoxicity in mice, Arch. Toxicol.
  57. Apostolopoulou, 2015, The role of mitochondria in statin-induced myopathy, Eur. J. Clin. Invest., 45, 745, 10.1111/eci.12461 · DOI
  58. Bouitbir, 2012, Mitochondria of trained skeletal muscle are protected from deleterious effects of statins, Muscle Nerve, 46, 367, 10.1002/mus.23309 · DOI
  59. Phillips, 2002, Statin-associated myopathy with normal creatine kinase levels, Ann. Intern. Med., 137, 581, 10.7326/0003-4819-137-7-200210010-00009 · DOI · Paper page
  60. Gambelli, 2004, Mitochondrial alterations in muscle biopsies of patients on statin therapy, J. Submicrosc. Cytol. Pathol., 36, 85
  61. Duncan, 2009, Decreased ubiquinone availability and impaired mitochondrial cytochrome oxidase activity associated with statin treatment, Toxicol. Mech. Methods, 19, 44, 10.1080/15376510802305047 · DOI
  62. Allard, 2018, Statins affect skeletal muscle performance: evidence for disturbances in energy metabolism, J. Clin. Endocrinol. Metab., 103, 75, 10.1210/jc.2017-01561 · DOI
  63. Galtier, 2012, Effect of a high dose of simvastatin on muscle mitochondrial metabolism and calcium signaling in healthy volunteers, Toxicol. Appl. Pharmacol., 263, 281, 10.1016/j.taap.2012.06.020 · DOI
  64. Parker, 2012, Effect of statins on creatine kinase levels before and after a marathon run, Am. J. Cardiol., 109, 282, 10.1016/j.amjcard.2011.08.045 · DOI
  65. Eijsvogels, 2014, Impact of statin use on exercise-induced cardiac troponin elevations, Am. J. Cardiol., 114, 624, 10.1016/j.amjcard.2014.05.047 · DOI
  66. Ernster, 1995, Biochemical, physiological and medical aspects of ubiquinone function, Biochim. Biophys. Acta, 1271, 195, 10.1016/0925-4439(95)00028-3 · DOI · Paper page
  67. Muraki, 1985, Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance, J. Appl. Physiol., 113, 479, 10.1152/japplphysiol.01362.2011 · DOI
  68. Schaefer, 2004, Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats, Toxicol. Appl. Pharmacol., 194, 10, 10.1016/j.taap.2003.08.013 · DOI
  69. Laaksonen, 1995, Serum and muscle tissue ubiquinone levels in healthy subjects, J. Lab. Clin. Med., 125, 517
  70. Marcoff, 2007, The role of coenzyme Q10 in statin-associated myopathy: a systematic review, J. Am. Coll. Cardiol., 49, 2231, 10.1016/j.jacc.2007.02.049 · DOI · Paper page
  71. Paiva, 2005, High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial, Clin. Pharmacol. Ther., 78, 60, 10.1016/j.clpt.2005.03.006 · DOI · Paper page
  72. Bogsrud, 2013, No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy, Scand. Cardiovasc. J., 47, 80, 10.3109/14017431.2012.756119 · DOI · Paper page
  73. Caso, 2007, Effect of coenzyme q10 on myopathic symptoms in patients treated with statins, Am. J. Cardiol., 99, 1409, 10.1016/j.amjcard.2006.12.063 · DOI · Paper page
  74. Tricarico, 2015, Mevalonate pathway blockade, mitochondrial dysfunction and autophagy: a possible link, Int. J. Mol. Sci., 16, 16067, 10.3390/ijms160716067 · DOI
  75. Puigserver, 2003, Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator, Endocr. Rev., 24, 78, 10.1210/er.2002-0012 · DOI · Paper page
  76. Meador, 2011, Statin-associated changes in skeletal muscle function and stress response after novel or accustomed exercise, Muscle Nerve, 44, 882, 10.1002/mus.22236 · DOI
  77. Ryter, 2019, Autophagy: a lysosome-dependent process with implications in cellular redox homeostasis and human disease, Antioxid. Redox Signal., 30, 138, 10.1089/ars.2018.7518 · DOI
  78. Halling, 2016, PGC-1alpha promotes exercise-induced autophagy in mouse skeletal muscle, Physiol. Rep., 4, 10.14814/phy2.12698 · DOI
  79. Andres, 2014, Mitophagy is required for acute cardioprotection by simvastatin, Antioxid. Redox Signal., 21, 1960, 10.1089/ars.2013.5416 · DOI
  80. Balaban, 2005, Mitochondria, oxidants, and aging, Cell, 120, 483, 10.1016/j.cell.2005.02.001 · DOI · Paper page
  81. Anderson, 2006, Type II skeletal myofibers possess unique properties that potentiate mitochondrial H(2)O(2) generation, Am. J. Physiol., Cell Physiol., 290, C844, 10.1152/ajpcell.00402.2005 · DOI · Paper page
  82. Shadel, 2015, Mitochondrial ROS signaling in organismal homeostasis, Cell, 163, 560, 10.1016/j.cell.2015.10.001 · DOI · Paper page
  83. Schirris, 2015, Statin-induced myopathy is associated with mitochondrial complex III inhibition, Cell Metab., 22, 399, 10.1016/j.cmet.2015.08.002 · DOI
  84. Westwood, 2005, Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity, Toxicol. Pathol., 33, 246, 10.1080/01926230590908213 · DOI
  85. Seachrist, 2005, Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity, Toxicol. Sci., 88, 551, 10.1093/toxsci/kfi305 · DOI
  86. Ji, 1991, Effect of exercise training on antioxidant and metabolic functions in senescent rat skeletal muscle, Gerontology, 37, 317, 10.1159/000213279 · DOI
  87. Dirks, 2006, Statin-induced apoptosis and skeletal myopathy, Am. J. Physiol. Cell Physiol., 291, C1208, 10.1152/ajpcell.00226.2006 · DOI
  88. Sacher, 2005, Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells, J. Pharmacol. Exp. Ther., 314, 1032, 10.1124/jpet.105.086462 · DOI
  89. Bonifacio, 2015, The AKT/mTOR signaling pathway plays a key role in statin-induced myotoxicity, Biochim. Biophys. Acta, 1853, 1841, 10.1016/j.bbamcr.2015.04.010 · DOI
  90. Zorov, 2014, Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release, Physiol. Rev., 94, 909, 10.1152/physrev.00026.2013 · DOI · Paper page
  91. Yu, 2016, Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination, Development, 143, 3050, 10.1242/dev.137075 · DOI · Paper page
  92. Bonifacio, 2017, IGF-1 prevents simvastatin-induced myotoxicity in C2C12 myotubes, Arch. Toxicol., 91, 2223, 10.1007/s00204-016-1871-z · DOI
  93. Verhees, 2011, Glycogen synthase kinase-3beta is required for the induction of skeletal muscle atrophy, Am. J. Physiol. Cell Physiol., 301, C995, 10.1152/ajpcell.00520.2010 · DOI
  94. Hanai, 2007, The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity, J. Clin. Invest., 117, 3940
  95. Mallinson, 2009, Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy, J. Physiol., 587, 219, 10.1113/jphysiol.2008.164699 · DOI
  96. Tuckow, 2011, Simvastatin represses protein synthesis in the muscle-derived C(2)C(1)(2) cell line with a concomitant reduction in eukaryotic initiation factor 2B expression, Am. J. Physiol. Endocrinol. Metab., 300, E564, 10.1152/ajpendo.00383.2010 · DOI
  97. Cederberg, 2015, Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort, Diabetologia, 58, 1109, 10.1007/s00125-015-3528-5 · DOI · Paper page
  98. Ridker, 2012, Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial, Lancet, 380, 565, 10.1016/S0140-6736(12)61190-8 · DOI · Paper page
  99. Satoh, 2014, Molecular mechanisms for the regulation of insulin-stimulated glucose uptake by small guanosine triphosphatases in skeletal muscle and adipocytes, Int. J. Mol. Sci., 15, 18677, 10.3390/ijms151018677 · DOI
  100. Hajduch, 2001, Protein kinase B (PKB/Akt)--a key regulator of glucose transport?, FEBS Lett., 492, 199, 10.1016/S0014-5793(01)02242-6 · DOI · Paper page
  101. Miinea, 2005, AS160, the Akt substrate regulating GLUT4 translocation, has a functional Rab GTPase-activating protein domain, Biochem. J., 391, 87, 10.1042/BJ20050887 · DOI · Paper page
  102. Smith, 2014, Simvastatin inhibits glucose metabolism and legumain activity in human myotubes, PLoS One, 9, 10.1371/journal.pone.0085721 · DOI
  103. Yaluri, 2016, Simvastatin induces insulin resistance in L6 skeletal muscle myotubes by suppressing insulin signaling, GLUT4 expression and GSK-3beta phosphorylation, Biochem. Biophys. Res. Commun., 480, 194, 10.1016/j.bbrc.2016.10.026 · DOI
  104. Sacheck, 2004, IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1, Am. J. Physiol. Endocrinol. Metab., 287, E591, 10.1152/ajpendo.00073.2004 · DOI · Paper page

Cited by

See all 136

Metadata

Authors
Bouitbir, J., Sanvee, G. M., Panajatovic, M. V., Singh, F., & Krähenbühl, S.
Venue
Pharmacological Research
Publisher
Elsevier BV
Published
2020-04
Volume
154
Pages
104201
ISSN
1043-6618
DOI
10.1016/j.phrs.2019.03.010
Cited by
136
References
35
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (31003A-156270)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanisms of statin-associated skeletal muscle-associated symptoms. https://app.cochat.ai/papers/10.1016/j.phrs.2019.03.010
The paper
Bouitbir, J., Sanvee, G. M., Panajatovic, M. V., Singh, F., & Krähenbühl, S. (2020). Mechanisms of statin-associated skeletal muscle-associated symptoms. Pharmacological Research. https://doi.org/10.1016/j.phrs.2019.03.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.